Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
A hunger for new experiences Narratives: Motivating Travel and Experience - 2The most effective method to Use an Internet Showcasing Degree for Advanced Predominance
- 3The Best 15 Applications for Efficiency and Association
- 4People are getting their news from AI – and it’s altering their views
- 5Polar bears are rewiring their own genetics to survive a warming climate
- The Most Compelling Books of the 10 years
- Public Parks in the USA
- Vote In favor of Your #1 Compelling Female Producer
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- The capacity to understand people on a profound level: Exploring Life's Intricacies
- Party Urban areas of the World
- The most effective method to Examine a Cellular breakdown in the lungs Finding with Family
- Dental Embed Innovation: An Achievement in Helpful Dentistry
- Weight-loss pill approval set to accelerate food industry product overhauls
